GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment

Current Drug Metabolism

Volumn 8, Issue 5, 2007, Pages 481-486

  Zarate R ^a   Gonzalez Santiago S ^b   de la Haba, J ^b   Bandres, E ^a   Morales, R ^b   Salgado, J ^a   Gomez A ^b   Aranda, E ^b   Garcia Foncillas J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Anthracycline; Breast cancer; Drug metabolizing enzymes; GSTP1; MTHFR; Polymorphisms

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DRUG METABOLIZING ENZYME; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; ANTINEOPLASTIC AGENT; GSTP1 PROTEIN, HUMAN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANOREXIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GRADING; CANCER STAGING; CARDIOTOXICITY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; EYE TOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; GENE FREQUENCY; GENE SEQUENCE; GENETIC IDENTIFICATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; RISK FACTOR; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING; ARTICLE; BREAST TUMOR; GENETICS; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 34548798662     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920007780866780     Document Type: Review

References (37)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Lancet, 365 (9472), 1687-1717.
2. Piccart, M. (2003) Breast Cancer Res. Treat., 79 (Suppl 1), S25-34. Review.
3. Nagasubramanian, R.; Innocenti, F.; Ratain, M.J. (2003) Annu. Rev. Med., 54, 437-452. Review.
4. Caraco, Y. (1998) Ther. Drug Monit., 20(5), 517-524. Review.
5. Robert, J. (1994) Clin. Pharmacokinet., 26(6), 428-438. Review.
6. Pullarkat S.T.; Stoehlmacher, J.; Ghaderi, V.; Xiong, Y.P.; Ingles, S.A.; Sherrod, A.; Warren, R.; Tsao-Wei, D.; Groshen, S.; Lenz, H.J. (2001) Pharmacogenomics J., 1(1), 65-70.
7. Toffoli, G.; Veronesi, A.; Boiocchi, M.; Crivellari, D. (2000) Ann. Oncol., 11(3), 373-374.
8. Bernard, S.; Neville, K.A.; Nguyen, A.T.; Flockhart, D.A. (2006) Oncologist, 11(2), 126-135.
9. Goldhirsch, A.; Glick, J.H.; Gelber, R.D.; Coates, A.S.; Thurlimann, B.; Senn, H.J.; Panel members. (2005) Ann. Oncol., 16(10), 1569-1583.
10. Kim, J.W.; Lee, C.G.; Park, Y.G.; Kim, K.S.; Kim, Y.K.; Sohn, Y.W.; Min, H.K.; Min, H.K.; Lee, J.M.; Namkoong, S.E. (2000) Cancer, 88(9), 2082-2091.
11. Harries, L.W.; Stabbins, M.J.; Forman, D.; Howard, G.C.; Wolf, C.R. (1997) Carcinogenesis, 18(4), 641-644.
12. Coughtrie, M.W.H.; Gilissen, R.A.H.; Shek, B.; Strange, R.C.; Fryer, A.A.; Jones, P.W.; Bamber, D.E. (1999) Biochem. J., 337(1), 45-49.
13. Horie, N.; Aiba, H.; Oguro, K.; Hojo, H.; Takeishi, K. (1995) Cell Struct. Funct., 20(3), 191-197.
14. Ulrich, C.M.; Bigler, J.; Velicer, C.M.; Greene, E.A.; Farin, F.M.; Potter, J.D. (2000) Cancer Epidemiol. Biomarkers Prev., 9(12), 1381-1385.
15. Yi, P.; Pogribny, I.; Jill, J.S. (2002) Cancer Lett., 181(2), 209-213.
16. Cascorbi, I.; Gerloff, T.; Johne, A.; Meisel, C.; Hoffmeyer, S.; Schwab, M.; Schaeffeter, E.; Eichelbaum, M.; Brinkmann, U.; Roots, I. (2001) Clin. Pharmacol. Ther., 69(3), 169-174.
17. Tofteng, C.L.; Kindmark, A.; Brandstrom. H.; Abrahamsen, B.; Petersen, S.; Stiger, F.; Stilgren, L. S. Jensen J.E.; Vestergaand, P.; Langdahl, B.L.; Mosekilde, L (2004) Calci. Tissue Int., 74(1), 25-34.
18. Sant, M.; Capocaccia, R.; Coleman, M.P.; Berrino, F.; Gatta, G.; Michell, A.; Verdecchia, A.; Faivre, J.; Hakulinen, T.; Coebergh, J.W.; Martinez-Garcia, C.; Forman, D.; Zappone, A.; EUROCARE Working Group. (2001) Eur. J. Cancer, 37(13), 1659-1667.
19. Hershman, D.; Weinberg, M.; Rosner, Z.; Alexis, K.; Tiersten, A.; Grann, V.R.; Troxel, A.; Neugut, A.I. (2003) J. Natl. Cancer Inst., 95(20), 1545-1548.
20. McCollum, A.D.; Catalano, P.J.; Haller, D.G.; Mayer, R.I.; Macdonald, J.S.; Benson, A.B. 3rd.; Fuchs, C.S. (2002) J. Natl. Cancer Inst., 94(15), 1160-1167.
21. Stochlmacher, J.; Park, D.J.; Zhang, W.; Groshen, S.; Tsao-Wei, D.D.; Yu, M.C.; Lenz, H.J. (2002) J. Natl. Cancer Inst., 94(12), 936-942.
22. Watson, M.A.; Stewart, R.K.; Smith, G.B.; Massey, T.E.; Bell, D.A. (1998) Carcinogenesis, 19(2), 275-280.
23. Driven, H.A.; Van Ommen, B.; Van Bladeren, P.J. (1994) Cancer Res., 54(23), 6215-6220.
24. Subramaniam, S.; Subramaniam, S.; Shyamala Devi, C.S. (1944) Cancer Biochem. Biophys., 14(3), 177-1182.
25. Robert, J. (1993) Drugs, 45(Suppl 2), 20-30.
26. Kinnula, K.; Linnainmaa, K.; Raivio, K.O.; Kinnula, V.L. (1998) Br. J. Cancer, 77(7), 1097-1102.
27. McIlwain, C.C.; Townsend, D.M.; Tew, K.D. (2006) Oncogene, 25(11), 1639-1648.
28. Sweeney, C.; McClure, G.Y.; Fares, M.Y.; Stone, A.; Coles, B.F.; Thompson, P.A.; Korourian, S.; Hutchins, L.F.; Kadlubar, F.F.; Ambrosone, C.B. (2000) Cancer Res., 60(20), 5621-5624.
29. Wang, L.; Groves, M.J.; Hepburn, M.D.; Bowen, D.T. (2000) Haematologica, 85(6) 573-579.
30. Frosst, P.; Blom, H.J.; Milos, R.; Goyette, P.; Sheppard, C.A.; Matthews, R.G.; Boers, G.J.; den Heijer, M.; Kluijtmans, L.A.; van den Heuvel, L.P. (1995) Nat. Genet., 10(1), 111-113.
31. Weisberg, I.; Tran, P.; Christensen, B.; Sibani, S.; Rozen, R. (1998) Mol. Genet. Metab., 64(3), 169-172.
32. Sohn, K.J.; Croxford, R.; Yates, Z.; Lucock, M.; Kira, Y.I. (2004) J. Natl. Cancer Inst., 96(2), 134-144.
33. Etienne, M.C.; Ilc, K.; Formento, J.L.; Laurent-Puig, P.; Formento, P.; Cheradame, S.; Fischel, J.L.; Milano, G. (2004) Br. J. Cancer, 90(2), 526-534.
34. Keku, T.; Millikan, R.; Worley, K.; Winkel, S.; Eaton, A.; Biscocho; L.; Martin, C.; Sandler, R. (2002) Cancer Epidemiol. Biomarkers Prev., 11(12), 1611-1621.
35. Wilcken, B.; Bamforth, F.; Li, Z.; Zhu, H.; Ritvanen, A.; Renlund, M.; Stoll, C.; Alembik, Y.; Dott, B.; Czeizel, A.E.; Gelman-Kohan, Z.; Scarano, G.; Bianca, S.; Ettore, G.; Tenconi, R.; Bellato, S.; Scala, I.; Mutchinick, O.M.; Lopez, M.A.; de Walle, H.; Hofstra, R.; Joutchenko, L.; Kavteladze, L.; Bermejo, E.; Martinez-Frias, M.L.; Gallagher, M.; Erickson, J.D.; Vollset, S.E.; Mastroiacovo, P.; Andria, G.; Botto, L.D. (2003) J. Med. Genet., 40(8), 619-625.
36. Via, M.; Lopez-Alomar, A.; Valveny, N.; Gonzalez-Perez, E.; Bao, M.; Esteban, E.; Pinto, X.; Domingo, E.; Moral, P. (2003) Am. J. Med. Genet. A, 116(3), 243-248.
37. Stearns, V.; Davidson, N.E.; Fleckhart, D.A. (2004) Pharmacogenomics J., 4(3), 143-153. Review.